TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21788422

Group type: EXPERIMENTAL
Intervention: ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada), 0.5-mL dose
Number of subjects: 138
Study: 21788584

Group type: EXPERIMENTAL
Intervention: Low-WSS segments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-WSS segments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermediate-WSS segments
Number of subjects: 20
Study: 21789167

Group type: EXPERIMENTAL
Intervention: Severely burned pediatric patients
Number of subjects: 977

Group type: COMPARATOR
Intervention: Non-burned, non-injured children
Number of subjects: 977
Study: 21789604

Group type: EXPERIMENTAL
Intervention: Self-collected vaginal swabs
Number of subjects: 190

Group type: COMPARATOR
Intervention: Practitioner-collected swabs
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Self-collected swabs for high concentrations of A. vaginae (≥10^8 copies/mL)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Self-collected swabs for high concentrations of G. vaginalis (≥10^9 copies/mL)
Number of subjects: 190
Study: 21791058

Group type: EXPERIMENTAL
Intervention: Motesanib 100 mg QD + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD + erlotinib (150 mg QD)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD) + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg QD) + motesanib (100 or 125 mg QD)
Number of subjects: 56
Study: 21791415

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) in reduced-intensity conditioning
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Patients with ScGVHD
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Greater body surface area involvement in patients with ScGVHD
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Platelet count and C3 levels in patients with ScGVHD
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Forced vital capacity in patients with ScGVHD
Number of subjects: 206
Study: 21791424

Group type: EXPERIMENTAL
Intervention: Global chronic GVHD severity (mild, moderate, severe) at enrollment
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Global severity scores at enrollment
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 2-year overall survival based on global severity scores
Number of subjects: 298
Study: 21791425

Group type: EXPERIMENTAL
Intervention: Infusion of highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2; median number of infused NK cells was 2.74 × 10(6)/Kg; T cells were < 10(5)/Kg.
Number of subjects: 13
Study: 21791469

Group type: EXPERIMENTAL
Intervention: Bortezomib treatment
Number of subjects: 469
Study: 21791473

Group type: EXPERIMENTAL
Intervention: Deferiprone 15 mg/kg bid
Number of subjects: 6
Study: 21791475

Group type: EXPERIMENTAL
Intervention: Cytarabine 400 mg/m(2)/day for 5 days + Tanespimycin 300 mg/m(2) on days 3 and 6
Number of subjects: 26
Study: 21791513

Group type: EXPERIMENTAL
Intervention: Oral antiplatelet therapy (OAT) interruption for more than 5 days prior to surgery
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Preoperative haemoglobin <10 g/dl
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Creatinine clearance <30 ml/min
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Emergency or high-risk surgery
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Creatinine clearance between 30 and 60 ml/min
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Delay from stent implantation to surgery <3 months
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: High-risk surgery according to the Lee classification
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Overall incidence of MACCE
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Overall incidence of major bleeding complications
Number of subjects: 1134
Study: 21791540

Group type: EXPERIMENTAL
Intervention: Plasma NGAL
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Plasma NGAL and BNP combination
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Plasma NGAL and BNP elevated
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Low BNP and high NGAL
Number of subjects: 186

Group type: COMPARATOR
Intervention: Serum creatinine and eGFR
Number of subjects: 186
Study: 21791546

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adalimumab (ADA) and Etanercept (ETA)
Number of subjects: 48
Study: 21791591

Group type: EXPERIMENTAL
Intervention: Cirrus OCT system
Number of subjects: 112

Group type: COMPARATOR
Intervention: Spectralis OCT system
Number of subjects: 112
Study: 21791687

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of sentinel lymph nodes (SLNs) for tumor detection
Number of subjects: 5210

Group type: EXPERIMENTAL
Intervention: Immunocytochemical staining of bone marrow for tumor detection
Number of subjects: 5210
Study: 21794112

Group type: EXPERIMENTAL
Intervention: Implementation of a multi-country prospective observational study (GRACE-01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solutions implemented in the study
Number of subjects: 0
Study: 21794906

Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula-2 (FAHF-2), 3.3 g (6 tablets) three times a day for 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Food Allergy Herbal Formula-2 (FAHF-2)
Number of subjects: 18
Study: 21795476

Group type: EXPERIMENTAL
Intervention: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan (0.6 mg/m²/d) on days one to five of 21-day cycles
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan
Number of subjects: 24
Study: 21796719

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 205

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 205
Study: 21797863

Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium
Number of subjects: 656
Study: 21798054

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 120
Study: 21798965

Group type: EXPERIMENTAL
Intervention: Primary lateral sclerosis
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Amyotrophic lateral sclerosis
Number of subjects: 56

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 56
Study: 21799175

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet or gastric surgery
Number of subjects: 0
Study: 21799479

Group type: EXPERIMENTAL
Intervention: Leptin levels (ng/ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sleep duration and sleep efficiency measured by 2 weeks of wrist actigraphy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Respiratory disturbance index (RDI) assessed by a portable screening device
Number of subjects: 80
Study: 21799809

Group type: EXPERIMENTAL
Intervention: AMA1/C1-Alhydrogel+CPG 7909
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 8
Study: 21799847

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in patients with type 3 Gaucher disease
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Horizontal saccades
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Downward saccades
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oculo-manual dexterity scores on the Purdue Pegboard test
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vertical saccade peak duration vs amplitude slope
Number of subjects: 15
Study: 21801387

Group type: EXPERIMENTAL
Intervention: Abnormal glucose regulation diagnosed in-hospital (n = 105, 47%)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Abnormal glucose regulation diagnosed at three-month follow-up (n = 50, 25%)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis of survival free of composite end-points
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Clinical events during follow-up
Number of subjects: 224
Study: 21801411

Group type: EXPERIMENTAL
Intervention: Project FIT intervention (multi-faceted approach including school, community, social marketing, and school staff wellness)
Number of subjects: 403
Study: 21801604

Group type: EXPERIMENTAL
Intervention: Cervarix vaccine (three doses in Months 0, 1, and 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cervarix vaccine
Number of subjects: 30
Study: 21801857

Group type: EXPERIMENTAL
Intervention: Desogestrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 21802835

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg daily and continuously
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG status
Number of subjects: 41
Study: 21802881

Group type: EXPERIMENTAL
Intervention: Continuous monitoring using Nexfin finger cuff technology
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent monitoring using standard automated ED devices
Number of subjects: 40
Study: 21802924

Group type: EXPERIMENTAL
Intervention: Hydro-alcoholic extract of Lippia alba leaves, administered orally for 30-60 days.
Number of subjects: 0
Study: 21803569

Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily
Number of subjects: 1367
Study: 21804667

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) monitoring during nocturnal study
Number of subjects: 780
Study: 21805584

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with modern versions of the Carotid Wallstent and FilterWire EZ System
Number of subjects: 1097
Study: 21805607

Group type: EXPERIMENTAL
Intervention: Lumen Biomedical FiberNet® embolic protection system
Number of subjects: 20
Study: 21807867

Group type: EXPERIMENTAL
Intervention: Copeptin <14 pmol/L plus hscTnT <14 ng/L
Number of subjects: 503

Group type: COMPARATOR
Intervention: hscTnT alone
Number of subjects: 503
Study: 21808855

Group type: EXPERIMENTAL
Intervention: Mouth breathing group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nasal breathing group
Number of subjects: 55
Study: 21809989

Group type: EXPERIMENTAL
Intervention: Atypical teratoid/rhabdoid tumors (AT/RTs)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Medulloblastomas (MBs)
Number of subjects: 96
Study: 21811626

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Central venous catheter (CVC)
Number of subjects: 1001
Study: 21812019

Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 32
Study: 21812576

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) levels on admission
Number of subjects: 40
Study: 21812736

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 12 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg once daily for an additional 12 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg and 10 mg
Number of subjects: 25
Study: 21812775

Group type: EXPERIMENTAL
Intervention: Sumavel DosePro (needle-free subcutaneous sumatriptan) 6 mg
Number of subjects: 212
Study: 21812908

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 14
Study: 21812991

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with therapist support for 15 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with therapist support
Number of subjects: 23
Study: 21813383

Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (ICG-PDR)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Indocyanine green plasma disappearance rate (ICG-PDR) on day 7
Number of subjects: 86
Study: 21814460

Group type: EXPERIMENTAL
Intervention: Tiotropium (5 or 10 μg) via Respimat® Soft Mist™ Inhaler
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Placebo via Respimat® Soft Mist™ Inhaler
Number of subjects: 1990
Study: 21815133

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 40
Study: 21815182

Group type: EXPERIMENTAL
Intervention: Combination of decitabine, arsenic trioxide, and ascorbic acid
Number of subjects: 0
Study: 21815705

Group type: EXPERIMENTAL
Intervention: Atorvastatin lactone to atorvastatin acid ratio with a cut-off ratio set at 1.1
Number of subjects: 53
Study: 21816031

Group type: EXPERIMENTAL
Intervention: RTS, S malaria candidate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized assessment program for severe malaria
Number of subjects: 0
Study: 21816032

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria candidate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized laboratory methods and quality assurance processes
Number of subjects: 0
Study: 21816305

Group type: EXPERIMENTAL
Intervention: Single PCI strategy
Number of subjects: 668

Group type: COMPARATOR
Intervention: Staged PCI strategy
Number of subjects: 668
Study: 21816308

Group type: EXPERIMENTAL
Intervention: Early repolarization in patients with idiopathic ventricular fibrillation (IVF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Established cause of cardiac arrest
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serial ECGs
Number of subjects: 100
Study: 21816436

Group type: EXPERIMENTAL
Intervention: MSI colon cancer cells (HCT116)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSS colon cancer cells (HT29)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal colonic mucosa (NCM)
Number of subjects: 0
Study: 21816790

Group type: EXPERIMENTAL
Intervention: Amenorrheic athletes (AA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Eumenorrheic athletes (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonathletic controls
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight-bearing tibia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subject grouping
Number of subjects: 50
Study: 21816832

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with matched-related donors
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with matched-unrelated donors
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT with umbilical cord blood donors
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative HSCT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 6
Study: 21816833

Group type: EXPERIMENTAL
Intervention: New inhibitors of BCR signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCR signaling blockade
Number of subjects: 0
Study: 21816912

Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Free serum cortisol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Total serum cortisol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cortisol-binding globulin (CBG)
Number of subjects: 57
Study: 21818149

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 72

Group type: COMPARATOR
Intervention: Men
Number of subjects: 72
Study: 21818676

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT), 80 sessions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 10
Study: 21819438

Group type: EXPERIMENTAL
Intervention: Reduced GH secretion (n = 35)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sufficient GH secretion (n = 34)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal weight subjects (n = 33)
Number of subjects: 102
Study: 21819507

Group type: EXPERIMENTAL
Intervention: Intravitreal EPO injection (1000 IU/0.05 mL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (cataract surgery patients, 10 eyes of 10 patients)
Number of subjects: 11
Study: 21820136

Group type: EXPERIMENTAL
Intervention: Resting energy expenditure (REE)
Number of subjects: 108
Study: 21820279

Group type: EXPERIMENTAL
Intervention: Symptomatic atrial fibrillation (AF) management in the ED
Number of subjects: 430
Study: 21821014

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) in patients with CAD
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Red cell distribution width (RDW) in normal (No-CAD) patients
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) in patients with CAD
Number of subjects: 1489
Study: 21821340

Group type: EXPERIMENTAL
Intervention: Nutrition and lifestyle interventions
Number of subjects: 11991

Group type: EXPERIMENTAL
Intervention: Home-based health interview and examination survey
Number of subjects: 11991

Group type: EXPERIMENTAL
Intervention: 3-year prospective follow-up
Number of subjects: 11991
Study: 21821712

Group type: EXPERIMENTAL
Intervention: Cladribine 5.6 mg/m² IV over 2 hours daily for 5 days followed by rituximab 375 mg/m² IV weekly for 8 weeks
Number of subjects: 36
Study: 21823120

Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nodal DLBCL (control group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Primary breast DLBCL
Number of subjects: 25
Study: 21823912

Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ) at flexible doses (maximum 15 mg/day) for up to 16 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 96
Study: 21824425

Group type: EXPERIMENTAL
Intervention: cTnT elevation screening and coronary angiography within 72 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cTnT elevation screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ST-Elevation myocardial infarction
Number of subjects: 0
Study: 21824458

Group type: EXPERIMENTAL
Intervention: Short half-life antidepressants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antidepressant exposure
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall antidepressant exposure
Number of subjects: 21
Study: 21824941

Group type: EXPERIMENTAL
Intervention: Home delivery of radiology services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard radiology services)
Number of subjects: 0
Study: 21826527

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m²) on Day 1, vinorelbine (27.5 mg/m²) on Days 8 and 15, filgrastim (5 µg/kg) on Days 2-21, and weekly trastuzumab (2 mg/kg after an initial bolus of 4 mg/kg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Docetaxel, vinorelbine, filgrastim, and trastuzumab
Number of subjects: 74
Study: 21827541

Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors (diabetes, hypertension, obesity, dyslipidemia, smoking, family history)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Presence of cardiovascular risk factors
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Body mass index, diastolic blood pressure, age, and fasting plasma glucose
Number of subjects: 246
Study: 21828124

Group type: EXPERIMENTAL
Intervention: High VLA-4 expression
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Blocking of VLA-4 signaling in combination with cytarabine treatment
Number of subjects: 56
Study: 21828134

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 39
Study: 21828141

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m², four weekly applications)
Number of subjects: 28
Study: 21828142

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anti-PDGFRA antibodies
Number of subjects: 15
Study: 21828157

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 135

Group type: COMPARATOR
Intervention: Baseline ChBF
Number of subjects: 135

Group type: COMPARATOR
Intervention: Blood pressure response to isometric exercise
Number of subjects: 135

Group type: COMPARATOR
Intervention: Baseline arterial blood pressure
Number of subjects: 135
Study: 21829612

Group type: COMPARATOR
Intervention: riluzole
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: NNIPPS-PPS scale
Number of subjects: 760
Study: 21829931

Group type: EXPERIMENTAL
Intervention: Mean Length Utterance for words (MLU-w)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mean Length Utterance for morphemes (MLU-m)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Grammatical morphemes (GM) for articles, nouns and verbs (GM-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Grammatical morphemes (GM) for pronouns, prepositions and conjunctions (GM-2)
Number of subjects: 15
Study: 21831297

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch (dosage ratio of 1.5:1)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oral ropinirole
Number of subjects: 116
Study: 21831304

Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus (15 gm/day) for 8 weeks
Number of subjects: 20
Study: 21831685

Group type: EXPERIMENTAL
Intervention: Voriconazole therapy
Number of subjects: 25
Study: 21831743

Group type: EXPERIMENTAL
Intervention: autoSCT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: alloSCT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: RICE
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: FluBu
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 68
Study: 21831954

Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg QD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg QD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pazopanib (200-800 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 28
Study: 21832276

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 80
Study: 21833452

Group type: EXPERIMENTAL
Intervention: Recombinant IL-11 (rhIL-11, Neumega®) given subcutaneously for up to seven days during six consecutive menstrual cycles
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recombinant IL-11 (rhIL-11, Neumega®)
Number of subjects: 7